Sign In | Join Free | My
China Guangzhou Meisi New Material Co.,Ltd logo
Guangzhou Meisi New Material Co.,Ltd
Guangzhou Meisi New Material High quality, Best service, Reasonable price.
Verified Supplier

3 Years

Home > Active Pharmaceutical Ingredients >

191732-72-6 Lenalidomide

Guangzhou Meisi New Material Co.,Ltd
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment

191732-72-6 Lenalidomide

Brand Name : Meisi New Material

Place of Origin : China

MOQ : 100000KG

Payment Terms : T/T

Delivery Time : 5-8work days

Contact Now

Lenalidomide CAS No.191732-72-6

Product Name: Lenalidomide
Full English name:(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione

Chemical name: (3S) - 3 - (4-amino-1-oxo-1,3-dihydro-2h-isoindole-2-yl) piperidine-2,6-dione; (3S) - 3 - (4-amino-1-oxo-2-isoindolin) piperidine-2,6-dione

CAS No:191732-72-6
Molecular formula : C13H13N3O3
Molecular weight : 259.26062

Physical and chemical properties:

Melting point 269-271 ° C, density 1.460 ± 0.06 g / cm3.

Product category:

Lenalidomide is an anti-tumor drug developed by celgene biopharmaceutical company in the United States. Its chemical structure is similar to thalidomide, and it has multiple functions such as anti-tumor, immune regulation and anti angiogenesis. It can inhibit the secretion of pro-inflammatory cytokines and increase the secretion of anti-inflammatory cytokines of peripheral blood monocytes. In vitro experiments showed that the product could inhibit the proliferation of some cell lines such as Namalwa cells. Lenalidomide can inhibit the growth of multiple myeloma cells and MM1S cells. In addition, the product can also inhibit the expression of cyclooxygenase 2 (COX-2), but has no effect on COX-1. Two multicenter, randomized, blind, placebo-controlled clinical studies evaluated the safety and efficacy of lenalidomide in the treatment of multiple myeloma. The main outcome of the study was the mid-term analysis of TTP. The results showed that TTP in the combination group was significantly superior to that in the dexamethasone group. Recent clinical studies have shown that lenalidomide can be used in the treatment of MDS and mm as well as myeloma, leukemia, metastatic renal cancer, solid tumor, primary systemic amyloidosis and systemic myelofibrosis with myelometaplasia. Lenalidomide is a new generation derivative of thalidomide, but it has not been found that it has teratogenic toxicity, and its efficacy is 100 times stronger than thalidomide. According to the results of phase III clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of the patients can prolong their survival time to more than 3 years after taking the drug. In addition, it is also the only drug that can effectively treat myelodysplastic syndrome (MDS). Clinical results show that 64% of MDS patients use naduramine to treat MDS without blood transfusion.

Product Tags:

active pharma ingredients


medicine active ingredient

 191732-72-6 Lenalidomide Manufactures

191732-72-6 Lenalidomide Images

Inquiry Cart 0
Send your message to this supplier
*To: Guangzhou Meisi New Material Co.,Ltd
Characters Remaining: (0/3000)